Home|Journals|Articles by Year|Audio Abstracts

Case Report

Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation

Nithu M Kumar1, Priyanka Sreelatha1, Shine Sadasivan2, Ankur Jain2, Anila K N1.


Sorafenib is an oral multikinase inhibitor used as a palliative intent for advanced hepatocellular carcinoma (HCC). Dermatologic toxicity is the main adverse effect limiting its use in many patients. However, Grade III dermatologic toxicity is rarely seen with low-dose sorafenib administration. Here, we discuss the case of a 72-year-old male patient who was treated with sorafenib 400 mg for HCC. After 18 days of administration, the patient complained of intense pain with blisters and ulcerations. The drug was discontinued, and topical corticosteroids and analgesics were given for the management. Review of the patientÂ’s medication did not reveal the presence of any other possible drugs capable of producing dermatological toxicity.

Key words: Hepatocellular carcinoma; Sorafenib; Barcelona Clinic Liver Cancer Staging; Transarterial Chemoembolization

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.